InvestorsHub Logo

ziploc_1

07/28/22 4:26 AM

#384490 RE: Number sleven #384489

Nsleven...You are correct....Healthnet tripped over themselves with greed...

Healthnet figured they could lower their costs by putting an impediment in place for Docs to prescibe Vascepa for their patients by demanding a prior authorization,which they know many Docs are hesitant or unwilling to spend their time on.

Healthnet also correctly understood that the vast majority of scripts being written for Vascepa were for treating CVD rather than high triglycerides. They reasoned they could save money by reducing the number of scripts they had to pay for by demanding these prior authorizations.

This plan backfired when Docs wrote prior authorizations for the patients' CVD and Healthnet filled them with generic Vascepa... in clear infringement of Amarin's CVD patents.

Insurance companies all know that they are infringing on Amarin's CVD patents when they fill the prescriptions for Vascepa with the generic version, but they do it anyway to save money for themselves by dispensing the generic version, which they pay less for.

This time, Healthnet let their greed get the best of them.

Bolio98

07/29/22 6:55 AM

#384573 RE: Number sleven #384489

And when you have a jury deciding it instead of a Dusaster judge, your odds for winning go way up IMO.